Catégorie : Publications récentes

Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives, Carla Pallavicini et al., 2019

Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives Carla Pallavicini, Martina G. Vilas, Mirta Villarreal, Federico Zamberlan, Suresh Muthukumaraswamy, David Nutt, Robin Carhart-Harris, Enzo Tagliazucchi NeuroImage, 2019 https://doi.org/10.1016/j.neuroimage.2019.06.053 Abstract Classic serotonergic psychedelics are remarkable for their capacity to induce reversible alterations in consciousness of the self and the surroundings, mediated by agonism at serotonin 5-HT2A receptors. The subjective effects elicited by dissociative drugs acting as N-methyl-D-aspartate (NMDA) antagonists (e.g. ketamine and phencyclidine) overlap in certain domains with those of serotonergic psychedelics, suggesting some potential similarities in the brain activity patterns induced by both classes of drugs, despite different pharmacological mechanisms of action. We investigated source-localized [...]

Lire la suite

Prevalence and epidemiological associates of novel psychedelic use in the United States adult population, James D Sexton et al., 2019

Prevalence and epidemiological associates of novel psychedelic use in the United States adult population James D. Sexton, Michael S. Crawford, Noah W. Sweat, Allyson Varley , Emma E. Green and Peter S. Hendricks Journal of Psychopharmacology, 1-10 DOI : 10.1177/0269881119827796 journals.sagepub.com/home/jopract Abstract Background : Novel psychedelics approximate classic psychedelics, but unlike classic psychedelics, novel psychedelics have been used by humans for a shorter period of time, with fewer data available on these substances. Aims : The purpose of this study was to determine the prevalence of novel psychedelic use and the associations of novel psychedelic use with mental health outcomes. Methods : We estimated the prevalence of self-reported, [...]

Lire la suite

Disruptive Psychopharmacology, Jama Psychiatry, June 2019

Disruptive Psychopharmacology Boris D. Heifets, MD, PhD1; Robert C. Malenka, MD, PhD2 JAMA Psychiatry. Published online June 26, 2019. doi:10.1001/jamapsychiatry.2019.1145 The paucity of medications with novel mechanisms for the treatment of mental illnesses combined with the delayed response to currently available medications has led to great excitement about the potential therapeutic utility of previously demonized drugs, which offer the hope of generating rapid symptom reductions in some of the sickest patients. Within the past 2 years, the US Food and Drug Administration approved esketamine for treatment-resistant depression and 2 compounds that are still on the US Drug Enforcement Administration’s most restrictive schedule, 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin, [...]

Lire la suite

Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice, Adam L. Halberstadt et al., 2019

Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice Adam L. Halberstadt, Muhammad Chatha, Stephen J. Chapman and Simon D. Brandt Journal of Psychopharmacology, 2019, 1 –9 DOI: 10.1177/0269881119826610 journals.sagepub.com/home/jop Abstract Background : In recent years, there has been increasing scientific interest in the effects and pharmacology of serotonergic hallucinogens. While a large amount of experimental work has been conducted to characterize the behavioral response to hallucinogens in rodents, there has been little systematic investigation of mescaline and its analogs. The hallucinogenic potency of mescaline is increased by α-methylation and by homologation of the 4-methoxy group but it not clear [...]

Lire la suite

The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats, John Shallcross et al., 2019

The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats John Shallcross, Peter Hámor, Allison R. Bechard, Madison Romano, Lori Knackstedt and Marek Schwendt Frontiers in Behavioral Neuroscience, May 2019 | Volume 13 | Article 91 ORIGINAL RESEARCH published: 10 May 2019 doi: 10.3389/fnbeh.2019.00091 Post-traumatic stress disorder (PTSD) currently has no FDA-approved treatments that reduce symptoms in the majority of patients. The ability to extinguish fear memory associations is impaired in PTSD individuals. As such, the development of extinction-enhancing pharmacological agents to be used in combination with exposure therapies may benefit the treatment of [...]

Lire la suite

Medical Cannabis : Effects on Opioid and Benzodiazepine Requirements for Pain Control, Megan O’Connel et al., 2019

Medical Cannabis : Effects on Opioid and Benzodiazepine Requirements for Pain Control.  Megan O’Connell, PharmD, Megan Sandgren, PharmD, MS, BCPS, Leah Frantzen, PharmD, BCPS, Erika Bower, PharmD, BCACP, Brian Erickson, MD Annals of Pharmacotherapy, 2019 May 25:1060028019854221. doi: 10.1177/1060028019854221. PMID : 31129977 Abstract BACKGROUND : There is currently little evidence regarding the use of medical cannabis for the treatment of intractable pain. Literature published on the subject to date has yielded mixed results concerning the efficacy of medical cannabis and has been limited by study design and regulatory issues. OBJECTIVE: The objective of this study was to determine if the use of medical [...]

Lire la suite

Awareness of Emotional Expressions in Cannabis Users: An Event-Related Potential Study, Robert D. Torrence et al., 2019 ,

Awareness of Emotional Expressions in Cannabis Users : An Event-Related Potential Study Robert D. Torrence, Donald C. Rojas and Lucy J. Troup Frontiers in Psychology, February 2019 | Volume 10 | Article 69 ORIGINAL RESEARCH doi: 10.3389/fpsyg.2019.00069 Abstract Cannabis use has been associated with anxiogenic effects when used in low frequency for a short duration, but cannabis can also have anxiogenic effects when used heavily for a long duration. Animal studies have indicated the neurobiological mechanisms related to cannabis and anxiety; however, research has been limited on the related neurocognitive mechanisms. Previous research has indicated that cannabis use is associated with alterations in event-related potentials (ERPs). [...]

Lire la suite

Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states, Yuliya Zaytseva et al., 2019

Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states Zaytseva Y; Horáček J; Hlinka J; Fajnerová I; Androvičová R; Tintěra J; Salvi V; Balíková M; Hložek T; Španiel F; Páleníček T  Journal of Psychopharmacology, 2019, 33, 7, 811-821 Research Article  doi: 10.1177/0269881119849814. Abstract : Background : Cannabis, and specifically one of its active compounds delta-9-tetrahydrocannabinol in recreational doses, has a variety of effects on cognitive processes. Most studies employ resting state functional magnetic resonance imaging techniques to assess the stationary effects of cannabis and to-date one report addressed the impact of delta-9-tetrahydrocannabinol on the dynamics of whole-brain functional connectivity. Methods : Using a [...]

Lire la suite

IACM-Bulletin 22.06.2019

IACM-Bulletin 22.06.2019 http://www.cannabis-med.org/french/bulletin/ww_fr_db_cannabis_artikel.php?id=489 IACM-Bulletin du 22 Juin 2019 Etats-Unis: L'Illinois deviendra le 11ème État à légaliser la possession de cannabis chez les adultes Canada: Le gouvernement soutient la recherche sur le cannabis avec 25 millions de dollars Science/Homme: Le cannabis peut avoir un effet protecteur contre le diabète chez les personnes obèses Science/Homme: Les consommateurs de cannabis souffrant de troubles de la personnalité ne courent aucun risque accru de développer d'autres troubles psychiatriques En bref Un coup d'œil sur le passé Etats-Unis: L'Illinois deviendra le 11ème État à légaliser la possession de cannabis chez les [...]

Lire la suite

Cannabis Pharmacy. The Practical Guide to Medical marijuana, Michael Backes, 2014

Cannabis Pharmacy. The Practical Guide to Medical marijuana Authoritative, evidence-based information, plus advice on treating dozens of ailments and conditions Michael Backes, foreword by Andrew Weil, MD Black Dog & Leventhal Publishers, New York, 2014   Foreword by Andrew Weil, M.D. From the perspective of someone who has studied traditional therapies as a career, it is surprising that cannabis ever left our medicine cabinets, since the plant has been used for millennia in cultures throughout the world as a curative for ailments of both mind and body. In 1942, the American Medical Association (AMA) fought to keep it as part of the U.S. Pharmacopeia. In spite [...]

Lire la suite